Abstract Guidelines


Dr. ClohisyThe AAHKS Program Committee is looking for unpublished research study abstracts. The committee will be selecting abstracts for either podium or poster presentations. Authors of the abstracts selected for podium presentations have the opportunity to submit manuscripts for consideration of the James A. Rand Award, the Lawrence D. Dorr Award and the AAHKS Clinical Award. Authors also have the opportunity to submit manuscripts for the Journal of Arthroplasty (JOA) Proceedings of the Annual Meeting.

Submission Steps

  1. Log in or create a new account
  2. You can submit multiple abstracts (one at a time) and will be able to edit your submission until the submission deadline. Abstracts must be 300 words or less.
  3. Ensure that the names and email addresses of your co-authors are entered. If your abstract is chosen, co-authors will receive email notification regarding disclosure submission/update. If any of the author disclosures are missing, the abstract will be withdrawn from the final program.
  4. The AAHKS Program Committee follows a “blinded” abstract review process. Do not include names of institutions, cities or authors in the title or the text of the abstract.
  5. Abstracts may be submitted if you previously presented a paper at a national/international meeting; however, the work must be unpublished as of the start of the AAHKS Annual Meeting.

Abstract Format

Introduction

  1. Problem statement
  2. Statement of purpose/hypothesis of the study

Methods

  1. Study design (e.g., prospective-randomized, prospective cohort, retrospective cohort or case control)
  2. Sample size estimate for prospective studies
  3. Study group: inclusion/exclusion criteria, demographics, follow-up
  4. Data collection methods and statistical methods

Results

  1. Sufficient report of the data and results of the study
  2. P-values required for statements of statistical significance
  3. Statements of no significant difference should include an assessment of statistical power
  4. If inadequate sample size, state “with the numbers available for study.”

Conclusion

  1. What did the study show?
  2. Does the data support the conclusion and did the study answer the research question?

 

Abstract Selection and Grading Process

All abstracts will be reviewed in a blinded fashion. Each abstract in the given category will be evaluated and graded by five independent reviewers. The abstracts will be graded on a 25-point scale. Each score will be tallied, and scores will be averaged. The abstracts with the highest scores in each category will be selected for podium presentations. Several next-highest scored abstracts will be selected as poster presentations.

The grading scale assigns five maximum points for each of the following:

  1. Topic Importance and Originality
  2. Introduction: Purpose of paper and hypothesis is clearly stated.
  3. Methods: Study design (e.g., prospective-randomized, prospective cohort, retrospective cohort or case control) is clearly stated. Power analysis estimates for prospective studies are included. Study group is clearly described. Inclusion/exclusion criteria, demographics, and follow-up are noted. Data collection methods and statistical methods are described.
  4. Results: Results and associated data must be clearly and precisely described; appropriate p-values should be given.
  5. Conclusion: Study findings should be restated. Conclusion must indicate whether the data supported the study findings.

viewing postersDisclosure and Conflict of Interest

All abstract authors, co-authors and presenters are required to complete disclosures of their financial relationships with commercial interests prior to submitting abstracts. Authors, co-authors and presenters can submit their disclosure information on the American Academy of Orthopaedic Surgeons (AAOS) website. Disclosure information will be made available in the Final Program and Proceedings. Submissions of authors failing to disclose will be withdrawn from the program.

FDA Status

If a device or drug requiring FDA approval is included in the educational content, the content must include the FDA clearance status of the medical devices and pharmaceuticals for the uses discussed or described. “Off label” uses of a device or pharmaceutical may be described so long as the lack of FDA clearance for such uses is also disclosed. Posters exhibiting a Class III device or pharmaceutical require signage indicating the FDA status of the product.

 

HIPAA Compliance

Ensure that educational content complies with HIPAA (Health Insurance Portability and Accountability Act) to protect patient rights and confidentiality.